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Abstract
Long runs of homozygosity (ROH) are contiguous stretches of homozygous genotypes, which are a footprint of
inbreeding and recessive inheritance. The presence of recessive loci is suggested for Alzheimer’s disease (AD);
however, their search has been poorly assessed to date. To investigate homozygosity in AD, here we performed a ﬁnescale ROH analysis using 10 independent cohorts of European ancestry (11,919 AD cases and 9181 controls.) We
detected an increase of homozygosity in AD cases compared to controls [βAVROH (CI 95%) = 0.070 (0.037–0.104); P =
3.91 × 10−5; βFROH (CI95%) = 0.043 (0.009–0.076); P = 0.013]. ROHs increasing the risk of AD (OR > 1) were signiﬁcantly
overrepresented compared to ROHs increasing protection (p < 2.20 × 10−16). A signiﬁcant ROH association with AD risk
was detected upstream the HS3ST1 locus (chr4:11,189,482‒11,305,456), (β (CI 95%) = 1.09 (0.48 ‒ 1.48), p value =
9.03 × 10−4), previously related to AD. Next, to search for recessive candidate variants in ROHs, we constructed a
homozygosity map of inbred AD cases extracted from an outbred population and explored ROH regions in wholeexome sequencing data (N = 1449). We detected a candidate marker, rs117458494, mapped in the SPON1 locus, which
has been previously associated with amyloid metabolism. Here, we provide a research framework to look for recessive
variants in AD using outbred populations. Our results showed that AD cases have enriched homozygosity, suggesting
that recessive effects may explain a proportion of AD heritability.

Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder that is the leading cause of dementia worldwide1.
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AD presents a strong genetic component. Autosomal
dominant mutations have been linked to familial early
onset AD (EOAD) (<65 years): mutations in presenilin 1
(PSEN1)2, presenilin 2 (PSEN2)3, and amyloid precursor
protein (APP)4. These ﬁndings lead to the role of amyloid
metabolism as disease-causing mechanism5. Despite that,
dominant causes account for a minority of both familial
and sporadic EOAD cases, suggesting that autosomal
recessive loci might cause most EOAD cases (∼90%)6.
However, only two recessive mutations in the APP gene
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(A673V and E693Δ) have been described to date7,8, and
this mode of inheritance for AD remains controversial.
The sporadic form of late-onset AD (LOAD) (>65 years)
has a polygenic background. Heritability estimation for
LOAD is, roughly, 70%6. Although, near to 40 loci has
been associated with LOAD risk9–12, genetic variance
captured by genome-wide strategies fall in a range of
7 –31%9,13, explaining a limited part of disease heritability.
Current genetic ﬁndings were made using an additive
mode of inheritance, which overlooks the relevance of
non-additive genetic components, i.e., the recessive
model. Despite the fact these components could explain a
fraction of disease heritability.
It is well known that inbreeding increases the incidence
of recessive diseases. The probability of detecting a
recessive locus increases in offspring of consanguineous
unions14, because the partners share alleles identical-bydescent. This recent parental relatedness points to genuine regions of autozygosity. Long runs of homozygosity
(ROHs)—long stretches of consecutive homozygous
genotypes (>1 Mb)—are a recognized signature of recessive inheritance and provide a measure of inbreeding in
studied populations. Thus far, they have been used for
homozygosity mapping15. Population history, e.g., historical bottlenecks or geographical isolation, also inﬂuences
homozygosity levels in individual genomes16,17.
An excess of homozygosity has been associated with the
risk of AD in individuals of Caribbean-Hispanic and
African-American ancestries18–20, suggesting the presence of inbreeding and potentially autosomal recessive
AD (arAD) cases nested in these populations. Conversely,
this association was not replicated for individuals of
European ancestry21,22. Several factors might explain
these inconsistencies, among them it has been estimated
that large sample sizes (12,000‒65,000) are required to
detect an excess of homozygosity in outbred populations23. Thus, previous studies might be underpowered.
The limited number of deeply characterized consanguineous families, the difﬁculties in ﬁnding familial
information for sporadic AD individuals (mainly due to
the late onset of the disease) and the reduced size of
intragenerational pedigrees in western countries make the
search for recessive patterns of inheritance in AD complex. Furthermore, follow-up of candidate ROHs in
sequencing data might be a necessary step in the deﬁnitive
mapping of an arAD locus, but it has been poorly assessed
to date.
Assessing the impact of homozygosity in the genetic
architecture of AD, and subsequent follow-up of homozygous regions remains a challenge. To the best of our
knowledge, this is the largest genomic data set exploring
the inﬂuence of homozygosity in AD (n = 21,100). First,
we investigated whether AD individuals from a European
outbred population presented an excess of homozygosity
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relative to controls. Next, we measured the degree of
inbreeding in AD cases. To prioritize regions with
potential recessive loci, we constructed a homozygosity
map of genomic regions overrepresented in detected
inbred AD cases. Finally, we performed further exploration of several promising candidate ROHs using wholeexome sequencing (WES) data.

Patients and methods
The overview of the proposed strategy for ROH detection and subsequent prioritization is depicted in Fig. 1.
Genotyping data

This study includes 10 independent genome-wide data
sets comprising a total sample of 21,100 unrelated individuals (11,921 AD cases and 9181 individual controls) of
European ancestry (Supplementary Table 1). The
recruitment and phenotyping, has been described
previously12.
Genotype-level data for each cohort was processed by
applying identical quality control and imputation procedures, as previously reported12. Next, we generated a
merged data set combining imputed genotypes (MAF >
0.05; imputation quality R2 > 0.90) from available data
sets. We calculated identity-by-descendent (IBD) with
PLINK 1.9 to generate a cohort of unrelated individuals of
European ancestry (Supplementary Fig. 1). All possible
pairs had Pi-hat < 0.1875, a Z0 ≥ 0.75 and a Z1 ≤ 0.25.
Imputed markers with call rates >0.95 and MAF > 0.05 in
the merged data set were selected for ROH calling
(NSNPs = 2,678,325).
Runs of homozygosity (ROHs) exploration
1-Identiﬁcation of individual ROHs

Individual ROH calling was conducted using the
observational genotype-counting approach implemented
in PLINK (v1.09) (https://www.cog-genomics.org/plink/1.9/),
as it outperforms additional methods in ROH detection
and it is applicable to outbred populations24. ROH
detection was performed for each individual study and
for the merged data set using imputed genotypes. We
used a sliding window of 50 SNPs of 5000 Kb in length to
scan the genome. In order to manage genomic regions
with a small number of genotyping errors and discrete
missingness, one heterozygote and ﬁve missing calls per
window were tolerated. These parameters were similar to
those described previously25. The minimal number of
SNPs in a ROH was set to 100 SNPs26,27. We empirically
explored two minimal length cut-offs to consider a ROH,
1 Mb and 1.5 Mb. ROHs < 1.5 Mb might reﬂect LD patterns of ancient origin rather than the consanguineous
cultural practices and genetic isolation captured with
ROHs > 1.5 Mb28. SNPs were included in a ROH if >5%
of the sliding window was homozygous. The maximum
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GWAS data
21,102 individuals

WES data
1,449 individuals

6a. Gene Based
Strategy

1. Individual ROHs
≥ 1.5 Mb
≥ 100 SNPs
2. Homozygosity
Parameters
SF3-SF4-SF5

4.a. HP vs AD

6b. Variant Filtering
Strategy
807 ROHs; 1,722 Genes

Coding and flanking variants for candidate
ROH regions

3. Consensus ROHs
21,190
FROH > 0.0156
(2nd degree
relave)

Minor
Minor
Allele
Allele
Frequency
Frequency
< 0.01
< 0.01

5. 958 inbred AD
cases; 5,087
consensus ROHs
SF7

4.b. Consensus ROH
vs AD

> 0.1Mb
> 100 SNPs

High or Moderate
Impact Variants

Homozygous variants

Gene-Based Analysis
SKAT-O

Variants only present
in AD individuals

32 Genes > 3 Variants
in the model

Variants present in
ROHs

≥ 2 SNPs
Beta > 0.03
> 0.1Mb
> 3 SNPs

12 ROH
in/near

AD loci

795 ROH
Non-AD loci

11 ROH
in/near

AD loci

1,006 ROH
Non-AD loci
P < 0.05

1,722 Genes

33 ROHs
32 Genes

Fig. 1 Schematic of the stepwise for ROH prioritization. 1. Identiﬁcation of ROH segments per individual; 2. Estimation of: homozygosity
parameters, and 3. Consensus ROHs; 4. Association analysis between: a) Homozygosity parameters and AD status, and b) Consensus ROH and AD
status; 5. Identiﬁcation of inbred AD cases and ROH prioritization; 6. Exploration of selected ROH segments in WES data applying: a) Gene-based
strategy, and b) Variant ﬁltering strategy.

distance between two consecutive SNPs was set to
1000 Kb apart, and SNP density to at least 1 SNP in
50 Kb.
2-Exploration of homozygosity parameters

To assess the data quality and genetic architecture of
detected ROHs (>1 Mb and >1.5 Mb) in each individual
study and in the whole dataset, we calculated: (a) the
mean of the total length of ROH or sum of ROH (SROH);
(b) the average ROH length (AVROH); (c) the number of
ROHs (NROH); and (d) ROH-based estimates of the
inbreeding coefﬁcient, F, (FROH) per individual. AVROH
is the SROH divided by NROH per subject. FROH
represents the proportion of homozygous segments in the
autosomal genome per individual (Eq. 1). For individuals,
this would be the SROH detected divided by a factor of
3,020,190 Kb, the total autosomal genome length
according to the GRCh37.p13 assembly. We further
explored whether the effect of homozygosity parameters
was similar when: (1) ROH length was set to 1 or 1.5 Mb;
and (2) the analysis was performed per data set or in the
ﬁnal merged database. Results emerging from these

exploratory analyses are shown in Supplementary Figs. 2–3,
Supplementary Tables 2–3, and Supplementary Methods. According to them, we decided to conduct downstream analyses with ROH calling at 1.5 Mb in the
merged data.

F ROH ¼

SROHðKbÞ
Autosomal genome ðKbÞ

ð1Þ

Copy number variants (CNV), particularly hemizygous
deletions, are known to cause spurious ROHs. However,
prior studies have demonstrated that the impact of performing ROH calling with or without CNVs is only 0.3%
of the total ROH length28. To assess the impact of CNVs
deletions, we also conducted ROH calling after removing
common CNV deletions extracted from the Database of
Genomic Variants (DGV) (http://dgv.tcag.ca/)29. The
same exercise was conducted after removing CNVs
detected in GR@ACE dataset. Further description of CNV
calling is provided in Supplementary material.
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3-Identiﬁcation of consensus ROHs

5-The homozygosity map of inbred AD individuals

Consensus ROHs were deﬁned as overlapping segments
between individual ROHs observed in different individuals, with DNA segment match of at least 95% for nonmissing SNP markers. Consensus ROH calling was performed using PLINK 1.9. To prevent the detection of
false-positive ROHs, we extracted those consensus ROHs
with a length >100 Kb and >3 SNPs.

5a-Identiﬁcationn of inbred individuals We used FROH
to detect the subset of inbred individuals within our
dataset. FROH has been previously shown to better
correlate with the unobserved pedigree inbreeding23,31.
The cut-off between inbred and non-inbred individuals
was set to FROH > 0.015632, which corresponds to a
second-degree relation. It was assumed that there are no
different biological effects below 0.0156 than in the general
population33. The efﬁcient capture of inbred individuals is
shown in Supplementary Fig. 7. Next, to explore whether
the frequency of consanguinity was higher in AD cases
than in controls, we calculated the odds ratio and chi
square p values using the epitools package in R.

4-Analyses

4a-Association analysis between homozygosity parameters and AD risk To assess the quality of the data in
each individual study, we explored sample distribution for
each of four homozygosity parameters: NROH, SROH,
AVROH, and FROH. An exploratory analysis was
depicted with violin plots, which combine a box plot
with a kernel density plot, using the ggplot2 package from
R (Supplementary Figs. 4 and 5). The inverse rank normal
transformation was performed to generalize homozygosity parameters using “rankNorm” option in the RNOmni
package in R. Transformed distributions are shown in
Supplementary Fig. 6. To test the association of homozygosity parameters with AD status, we developed a
generalized linear model for a binominal outcome, using
R for individual-level data. We tested three models,
adjusting per: (1) cohort and the ﬁrst four principal
components (PCs) resulting from ancestry analysis. See
Eq. 2; (2) cohort, PCs and age; (3) cohort, PCs, age and
gender. We also conducted a sensitivity analysis excluding
control individuals <60 years old (See the “Results”
section),
Z ¼ β1 Homozygosity Parameter þ β2 Cohort
þβ3 PC1 þ β4 PC2 þ β5 PC3 þ β5 PC4 þ e

ð2Þ

4b-Association analysis between consensus ROHs and
AD The association between the phenotype and consensus ROHs was explored using a logistic model, for
ROHs in or near to previously identiﬁed AD loci
extracted from de Rojas et al.30 and non-AD ROHs.
The model was adjusted per cohort, and the ﬁrst four
PCs as covariates for downstream analysis. Covariate
models adjusted for age and gender, in addition to
cohort and PCs, were also calculated. Regression-based
results were corrected for multiple testing using a
Bonferroni correction.
Next, we sought to estimate whether there was an
overrepresentation of risk (β > 0) or protective (β < 0)
consensus ROHs in our association results at different
levels of length and SNP number per consensus ROH. We
applied a binominal test using R.

5b-ROHs prioritization based on inbred AD cases
ROH detection was conducted in the subset of inbred AD
cases, applying similar criteria to those previously
described. Brieﬂy, considering the long size of homozygous
tracts for inbred individuals, there is a higher probability of
ﬁnding a consensus ROH by chance within consanguineous
AD cases than in the general population. Hence, we applied
stringent criteria to deﬁne consensus ROHs. Consensus
ROHs from inbred AD cases with ROH lengths >100 Kb
and ROH > 100 SNPs were given priority for further
analysis. Shared overlapping regions between inbred AD
cases and the whole data set were also identiﬁed (See bash
code in Supplementary Code Material) and selected based
on their overrepresentation in AD cases relative to controls
(β > 0.03). Prioritized regions were then explored in
sequencing data. We also explored the overlapping of
these regions with previously identiﬁed AD loci30.

WES data

To meet the objective of exploring most promising
ROH candidates in the sequencing data, we used the
Knight-ADRC-NIA-LOAD (KANL) cohort34. We excluded autosomal dominant familial cases and sporadic AD
cases harboring well-known disease-causing mutations, as
they could explain disease status. Thus, this study comprised 986 AD cases and 463 control individuals of European ancestry (See Supplementary Table 1 and
Supplementary Fig. 1). Of these, 488 subjects presented
both GWAS and WES data available for this study.
Detailed descriptions of cohort characteristics and quality
control for WES data have been provided previously34.
6-Candidate gene prioritization strategies using WES

6a-Gene-based analysis To prioritize genes in consensus ROH regions, we performed gene-based analysis (986
cases vs 463 controls) (Fig. 1). To generate variant sets,
variants were ﬁltered out according to minor allele
frequency (MAF < 0.01) and functional impact. The allele
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frequency cut-off was established according to the Exome
Aggregation Consortium (ExAC), non-Finnish European
Exome Sequencing project (ESP), and 1000 G. Only those
variants predicted to have a high or moderate effect
according to SnpEff were included35. To compute pvalues per gene set, SKAT-O model was applied using R.
The models were adjusted to consider the impact of the
ﬁrst two PCs and sex. Genes were ﬁltered out from results
if the number of variants included in the model was ≤3.
6b-Variant ﬁltering strategy for inbred AD cases with
WES and GWAS data available ROH segments emerging from inbred AD cases are the most promising
candidates to harbor autosomal recessive variants. Therefore, we deeply explored ROHs by applying a variant
ﬁltering strategy. We explored 488 AD cases with
complementary GWAS and WES data. Because there is a
low likelihood to identify any novel or causative mutation
in available databases, variants with MAF > 0.01 were
excluded. All heterozygous variants were removed. Finally,
only the variants mapped in individual ROHs were selected.
To map genes within ROHs, we ﬁrst extracted all the
variants located in ROH regions. Next, we individually
annotated each one.
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21,100 unrelated European individuals from 10 independent cohorts (Supplementary Tables 1–2 and Supplementary Fig. 4). Relationships between the mean NROH
and SROH are shown in Fig. 2. The mean NROH was
14.6 ± 4.6, the AVROH was 2.11 ± 0.61 Mb, and the
SROH was 31.9 ± 22.2 Mb. These estimations are in
accordance with those observed in European individuals32, except for the NROH parameter, which was
higher than in the previous studies32.
Next, we tested the association of the four homozygosity
parameters with AD risk. We found that (i) higher
inbreeding coefﬁcient (FROH) increased the risk of suffering
AD [βFROH (CI95%) = 0.043 (0.009–0.076); p value = 0.013]
(Table 1); (ii) AD patients presented higher average lengths
of ROHs compared to controls [βAVROH (CI95%) = 0.07
(0.037–0.104); p value = 3.91 × 10−5]; (iii) ROH number was
not associated with AD risk after adjusting for age [βNROH
(CI 95%) = 0.010 (−0.024–0.044); p value = 0.571] (Table 1).
Results per cohort are shown in Supplementary Table 4.
Notably, a sensitivity analysis conducted excluding: (1)
known deletions, i.e., hemizygous segments29; and, (2) deletions identiﬁed in GR@ACE CNV study; provided comparable results (Supplementary Table 5). After excluding control
individuals <60yo, a stable and signiﬁcant effect remains for
AVROH [βAVROH (CI 95%) = 0.07 (0.031–0.103); p value =
3.51 × 10−5] (Supplementary Table 5).

Results
ROH parameters are associated with AD risk

ROH analysis of AD risk using the whole data set

We examined the typical characteristics of the four
ROH parameters (SROH, NROH, AVROH, FROH) in

We identiﬁed 21,190 consensus ROHs in the merged
data set (N = 21,100). We observed a signiﬁcant over-

A

B

Fig. 2 Runs of homozygosity per cohort and per individual. A Mean number of ROHs versus mean total sum of ROHs in Mb for the 10 cohorts
explored. B Mean number of ROHs versus mean total sum of ROHs in Mb per individual explored. Red dashed lines represent the threshold for the
inbreeding coefﬁcient of 0.0156 (second cousins’ offspring) and 0.0625 (ﬁrst cousins’ offspring).
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Table 1 Effect of genome-wide homozygosity measures in Alzheimer’s disease for the joint analysis.
Dataset

Model 1

FROH

Model 2

Model 3

Beta (CI 95%)

P value

Beta (CI 95%)

P value

0.051 (0.023–0.078)

3.25 × 10−4

0.044 (0.010–0.077)

0.011
−5

Beta (CI 95%)

P value

0.043 (0.009–0.076)

0.013

AVROH

0.027 (0.000–0.055)

0.051

0.074 (0.040–0.106)

2.16 × 10

0.070 (0.037–0.104)

3.91 × 10−5

NROH

0.043 (0.015–0.071)

2.48 × 10−3

0.010 (−0.024–0.044)

0.559

0.010 (−0.024–0.044)

0.571

Model 1: adjusted per Cohort and PCs; Model 2: Adjusted by cohort, PCs, and age; Model 3: Adjusted by cohort, PCs, age and gender.
Results for the association of excess of homozygosity (FROH), average ROH lenght (AVROH), and number of ROH (NROH) with Alzheimer disease status.
OR, Odds ratio; with 95% conﬁdence interval (CI 95%) and level of statistical signiﬁcance (P value).
Association between homozygosity parameters and AD status, adjusted per Cohort, PCs, Age and Sex, was conducted in individuals with all available data; N = 19,253.

Table 2 Frequency of consensus ROHs with a potential risk or protective effect in Alzheimer’s disease.

Whole dataset
Category A
Category B

N ROH

Risk associations

Protective associations

P value

21190

11974

9216

< 2.2 × 10−16

1017
926

593
537

424
389

Probability of success

−16

< 2.2 × 10

−6

1.30 × 10

−6

Category C

858

499

359

1.98 × 10

Category D

42

33

9

2.7 × 10−4

Whole dataset/map of inbreed AD cases
Strategy
Strategy
Strategy
Strategy

6636

3969

2667

−16

< 2.2 × 10

0.56
0.58
0.57
0.58
0.79
0.60

A, ROHs > 100 kb; >3 SNPs.
B, ROHs > 100 kb; >25 SNPs.
C, ROHs > 100 kb; >50 SNPs.
D, ROHs > 100 kb; >3 SNPs, P < 0.05.

representation of ROHs increasing the risk of suffering
AD (p value < 2.20 × 10−16) (Table 2). The same overrepresentation of risk associations was detected after ﬁltering at several levels based on the length and number of
SNPs per consensus ROH (Table 2). When the test was
conducted with results adjusted for cohort, PCs, age, and
gender, the over-representation of risk associations
remained highly signiﬁcant (p value < 2.20 × 10−16).
We then tested the association of 11 consensus ROH
(≥100 Kb and ≥3 SNPs) located in or near to previously
identiﬁed AD loci (N = 38)30, with AD status (Supplementary Table 6). For these analyses, Bonferroni corrected signiﬁcance threshold of p = 1.32 × 10−3 was prespeciﬁed. We detected a strong association near to
HS3ST1 locus (consensus ROH length = 115.9 Kb;
chr4:11,189,482‒11,305,456), (45 AD cases vs 12 controls,
β (CI 95%) = 1.09 (0.48–1.48), p value = 9.03 × 10−4).
This region survived age and gender adjustments (Supplementary Table 6), and was detected across 12 out of 16
datasets (Supplementary Table 7). The replication of this
speciﬁc locus with AD, using ROH methodology, provides
new insights of a potential recessive mechanism for this
dementia locus. Among other ROH regions in or near to
known AD loci (Supplementary Tables 6 and 10), we
highlighted a 237 Kb ROH upstream the APP gene (chr21:

26,903,551–27,141,292), by its known role in AD7,8,36;
detected in 38 AD cases vs 26 controls (26 vs 12 inbred
individuals, respectively). For non-previously associated
AD regions, none ROH (N = 1006) reached the signiﬁcance threshold (Bonferroni correction of p = 4.97 ×
10−5). Previous signiﬁcant consensus ROH (chr8:
37835460–38143780) associated with AD in Europeans21
was not detected in this study, which is in line of results
from Sims et al.22, failing replication.
We then explored the genes located in signiﬁcant risk
consensus ROHs (p value < 0.05) in gene-based analysis
from WES data as well (Fig. 1). A total of 33 ROHs
comprising 32 genes were analyzed (included > 3 SNPs in
the model; Bonferroni correction p value = 0.0015). The
NECAB1 locus (chr8:91,803,921-91,971,630) presented
the most signiﬁcant signal (p = 0.01) (Supplementary
Table 8), but none loci reached the multiple test correction threshold.
Homozygosity mapping of AD using DNA segments
identiﬁed in inbred cases

We detected 1621 individuals (958 Cases and 663
Controls) presenting a FROH ≥ 0.0156 among the total
sample (N = 21,100) (Fig. 2) (Supplementary Table 9).
Interestingly, inbreeding over the second degree of
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Fig. 3 Circos plot for the prioritized regions. Histogram for the effect of the 21,190 consensus ROHs identiﬁed in the whole sample is shown. Risk
ROH associations are shown in red; protective ROH associations are shown in green. Blue regions represent prioritized ROHs from consanguineous
AD cases. Orange segments represent prioritized regions harboring potential recessive variants.

consanguinity was associated with a higher risk of suffering AD [OR (95%, CI) = 1.12 (1.01–1.25); p value =
0.027), which is in line with our previous results. This
supports the idea that an excess of consanguineous individuals is present in the AD population. Accordingly, the
search for recessive loci that play a role in AD can ﬁrst be
assessed in consanguineous cases.
After ROH calling in inbred AD cases, we detected 5087
ROHs, and extracted those with ≥100 Kb and ≥100 SNPs.
We then selected only over-represented regions in AD
cases relative to controls in the general analysis (Fig. 1).
We prioritized 807 consensus homozygous segments
from inbred cases (8.6% of the total autosomal genome)
(Fig. 3 and Supplementary Table 10). Among them, 12
ROHs were in or near to a previously identiﬁed AD loci
(Supplementary Table 10).
After exploring genes in identiﬁed ROHs by gene-based
analysis from WES data, none of them remained associated after multiple corrections (Ngenes tested = 1136; p
value = 3.47 × 10−5) (Supplementary Table 11). Our top
signal was detected in the FRY locus (p value = 0.001)
(Supplementary Table 11).
Considering that recessive variants are expected at very
low frequencies, even gene-based analysis would be
underpowered to detect signiﬁcant associations. Therefore, we decided to further prioritize loci by searching
homozygous mutations within selected consensus ROHs
from inbred AD subjects (Fig. 1). We identiﬁed seven AD
cases that had eight new (or extremely rare) homozygous

variants within long ROH segments (Table 3). All ROH
segments with homozygote variants were detected in
more than 6 cohorts. Two of these individuals were
consanguineous (FROH > 0.156). One had a missense variant (rs140790046, c.926A > G) that encodes p.Asn309Ser
change within the MKX locus. Another carried a rare
variant (rs116644203) in the ZNF282 locus, which was in
an extremely large region of homozygosity (14.9 Mb)
(Table 3). Furthermore, three additional homozygous
variants were detected: (i) a variant (rs117458494) in the
SPON1 locus, previously related with amyloid metabolism37, and (ii) two potential causative variants, carried
only by this individual, within a previously identiﬁed AD
region (TP53INP/NDUFAF6)12. One (rs73263258-ESRP1;
in TP53INP/NDUFAF6 region) is a missense variant
(c.475G > A) that encodes p.Ala159Thr change (Table 3).
Further notes and functional effect predictions for these
variants are provided in Supplementary Table 12.

Discussion
This study represents the largest analysis of homozygosity conducted for AD. Our estimates of homozygosity provide a robust evidence supporting that
recessive allelic architecture might deﬁne a portion of AD
heritability.
Previous AD ROH studies in European populations
have shown negative results for the association of ROH
parameters with AD21,22. First studies had very modest
sample sizes (N < 3000, vs Npresent study = 21,100)21,22, and
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likely were underpowered. Then, these studies used a
ROH calling lengths set to 1 Mb21,22. This generates
substantial inﬂation in the inbreeding coefﬁcient (FROH)
and makes undetectable the enrichment in consanguinity
due to unspeciﬁc noise (Supplementary material). These
reasons might explain initial failures. We encourage other
groups to conduct ROH analysis in new unrelated
populations, but with large enough sample sizes and
redeﬁning the ROH lengths at least to 1.5 Mb, to better
capture the recessive component of AD.
At the present study we identiﬁed a study-wise signiﬁcant ROH association close to the HS3ST1 gene
(~200 Kb). Genetic markers near to this ROH (~300 kb)
have been previously associated with AD using additive
models38,39, and HS3ST1 locus was differentially expressed in the brain of AD cases versus controls38. Our ﬁnding
reinforces the association of this region with AD, and
further suggests the role of recessiveness in explaining
underlying associations. High-resolution mapping across
this ROH could help to identify the causative mutation.
This study failed replication of previously detected ROH
at chr8:37835460–3814378021. Although, both studies
include TGEN cohort, overlapping to some extent, the
default technical parameters for ROH deﬁnition were
completely different (ROH calling: 1 Mb vs 1.5 Mb). We
assume that technical differences of the present study
respect to prior ones, might be critical points impacting
replication of ROH ﬁndings, in addition to other causes,
e.g. population-speciﬁc genetic patterns, or, even, random
chance.
A strength of the present study comes from our effort to
prioritize consensus ROHs according to the homozygosity
map of inbred AD individuals, performed by the ﬁrst time
in AD, and our capacity to explore them in sequencing
data. This strategy lets us to ﬁnd interesting candidate
recessive variants in: MKX and ZNF282 genes, identiﬁed
in two independent inbred AD cases; TP53INP1/NDUFAF6 genomic region, previously associated with AD12,40;
and SPON1 locus. The SPON1 locus deserves a further
explanation as it is directly related with APP metabolism,
a key player in AD physiopathology. APP cleavage
through β-secretases produces amyloid-beta (Aβ), which
later accumulates in AD brains5. SPON1 has been found
to bind to APP, inhibiting its α/β cleavage37, and to APOE
family of receptors41. Markers in this gene have been
related to dementia severity42 and with the rate of cognitive decline43. Considering prior ﬁndings and the present result, it would be biologically plausible that the
presence of recessive variants in APP7,8, or its biological
partners directly inﬂuences the amyloid cascade. Thus, we
believe that SPON1 could be considered an interesting
candidate, which deserves future resequencing efforts.
Our observations are subject to limitations that need to
be considered. Data sets used in this study were
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genotyped using different platforms and shared a small
proportion of directly genotyped markers. Given that
lower SNP density could impact the accuracy of the
study32, high quality imputed markers were used (r2 >
0.90, MAF > 0.05). Second, to reduce dataset heterogeneity we use a set of European individuals; applied the
same GWAS quality control per study; generated a
merged dataset including common variants across datasets; and controlled all our analyses by cohort, to account
with potential confounding.
We assumed that differences in the ROH parameters
between the cases and controls are modest. In that sense,
we are not expecting a very large percentage of recessive
AD cases, but we expect a fraction, in the same way, that it
occurs for autosomal dominant forms (<1%). Considering
that, the reported ﬁndings are supporting the hypothesis
of this work, a group of recessive mutation may explain a
portion of AD cases. However, we suspect that the existence of a large non-allelic heterogeneity is preventing its
identiﬁcation.
Our gene-based analysis strategy did not show signiﬁcant associations. With a decreasing allele frequency
and high locus heterogeneity, the power to detect genes of
interest also decreases. Despite our effort to include WES
data in the present study, the available sample size could
be underpowered.
The potential impact of CNV deletions on ROH analysis
must be taken into consideration. Thus, we assessed its
effect on our analyses, but no differences were found
before and after CNV exclusion (Supplementary Table 5),
which is in agreement with the previous studies25. Clonal
mosaicism, due to aging44, could also generate spurious
ROHs. At the present study an age-dependent increase in
the NROH was detected in the control group (Supplementary Table 13), which partially disappeared after
excluding consensus ROHs associated with age (p < 0.05)
(See Supplementary Material, and Supplementary Table
13 and 14). We assumed that these DNA segments might
contain somatic alterations, confounding ROH associations. Among age-related ROH regions, we identiﬁed
some loci previously associated with AD, e.g., RORA,
CD2AP, HS3ST1, and amyloid-beta burden, e.g., GLIS345;
suggesting that some known AD regions could be affected
by this phenomenon. These ﬁndings deserve future
investigations. Despite the existence of ROH segments
associated to age and somatic mosaicism phenomena, our
most signiﬁcant ﬁndings largely supported adjustments by
age. Therefore, we feel that the major observations of this
study are not affected by age-related instability of the
human genome.
In summary, we demonstrated the existence of an
inbreeding effect in AD and efﬁciently captured a fraction
of inbred individuals from outbred populations, providing
an improved strategy to look for recessive alleles, and to
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conduct future large-scale homozygosity mapping studies
in AD. Furthermore, the exploration of complementary
sequencing data gave an added value to this research,
providing a subset of potential candidates harboring
recessive variants. In any case, the proposed candidates
would need conﬁrmation in larger series. Greater efforts
and larger collections of individuals with GWAS and
sequencing data are needed to conﬁrm the present
ﬁndings.
Our understanding of the dynamics of population
genomics in AD is far from complete, but ROH analyses
provide us with a means to go further and might be an
alternative strategy to uncover the genetic loci
underlying AD.
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